 Home > Active Ingredient News > Antitumor Therapy > NEJM: Trastuzumab Deruxtecan in metastatic HER2-mutant non-small cell lung cancer

NEJM: Trastuzumab Deruxtecan in metastatic HER2-mutant non-small cell lung cancer

 Last Update: 2022-03-04
 Source: Internet
 Author: User

Tags

cell counter machine

lung development stages

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Most non-small cell lung cancers ( NSCLC ) are caused by oncogenic variants, and targeted therapies have greatly reduced mortality in NSCLC patients in recent years
.
Mutations in the gene encoding human epidermal growth factor receptor 2 (HER2, also known as ERBB2) are closely associated with approximately 3% of non-squamous NSCLC

Lung cancer NSCLC Compared with NSCLC patients without HER2 mutation or with other mutations, NSCLC patients with HER2 mutation have a slightly younger age of onset and a higher incidence of brain metastases .

This study is a multicenter, international phase 2 clinical trial to evaluate the efficacy and safety of trastuzumab deruxtecan (6.
4 mg/kg) in patients with metastatic HER2-mutant NSCLC refractory to standard therapy.
security
.
The primary endpoint was objective response rate as determined by an independent central review

median progression-free survival

A total of 91 patients were recruited
.
The median follow-up was 13.

1 months

Objective responses were achieved in 55% of patients

median overall survival

Drug safety was generally consistent with those reported in previous studies; 46% of patients experienced grade ≥3 drug-related adverse events, with the most common event being neutropenia (19%)
.
In addition, 26% of patients experienced drug-related interstitial lung disease, which resulted in 2 deaths

adverse event

Responses were observed in patients with different HER2 mutant subtypes, and also in patients with no detectable HER2 expression or HER2 amplification

In conclusion, trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated patients with HER2-mutant NSCLC

Trastuzumab deruxtecan exhibits durable anticancer activity in previously treated HER2-mutant NSCLC patients Trastuzumab deruxtecan exhibits durable anticancer activity in previously treated HER2-mutant NSCLC patients

Original source:

Bob T.

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer.
Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.